FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:316-319 July 20, 2006 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network PubMed Citation

To the Editor: The controlled trial of the use of corticosteroids in the acute respiratory distress syndrome (ARDS) by the National Heart, Lung, and Blood Institute (NHLBI) ARDS Clinical Trials Network (April 20 issue)¹ has limitations that affect the interpretability of the results. First, since only 180 of 3464 eligible patients (5 percent) were enrolled, the study population was not representative of those typically seen in clinical practice. Second, recent data demonstrate that patients with ARDS have excessive activation of nuclear factor-B, with excessive production of proinflammatory cytokines.² This imbalance between the proinflammatory and antiinflammatory responses is present from . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.